PALISADE BIO, INC.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
On September 25, 2026, we issued and sold 172,413 shares of our common stock, par value $0.01 per share, to the Crohn’s & Colitis Foundation (the “CCF”) for a total purchase price of $200,000, or a discounted stock price of $1.16 per share, pursuant to the Research Program Funding Agreement, which we entered into with the CCF on December 17, 2025.
The sale of the securities described above was exempt from registration under the Securities Act under Section 4(a)(2) of the Securities Act as transactions by an issuer not involving a public offering. No underwriters were involved in the sales.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.